Mariner
RLMD icon

Mariner’s Relmada Therapeutics RLMD Stock Holding History

Mariner’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,274
Closed -$39.8K – 3489
2024
Q3 		$39.8K Sell
12,274
-4,945
-29% -$16K ﹤0.01% 3212
2024
Q2 		$51.7K Sell
17,219
-6,771
-28% -$24.5K ﹤0.01% 3054
2024
Q1 		$112K Buy
23,990
+3,122
+15% +$15K ﹤0.01% 2909
2023
Q4 		$86.4K Sell
20,868
-2,385
-10% -$7.06K ﹤0.01% 2876
2023
Q3 		$69.8K Sell
23,253
-7,609
-25% -$22.6K ﹤0.01% 2734
2023
Q2 		$75.9K Buy
30,862
+6,007
+24% +$16.6K ﹤0.01% 2671
2023
Q1 		$56K Sell
24,855
-16,225
-39% -$55.9K ﹤0.01% 2649
2022
Q4 		$143K Buy
+41,080
New +$361K ﹤0.01% 2436

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mariner's RLMD Position: Q4 2024 in Review

Mariner sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 12,274 shares — an estimated $39.8K sold.

Mariner first reported a position in RLMD in Q4 2022 and held it in 8 quarters. The position peaked at $143K in Q4 2022. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

  • Mariner reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Mariner sold 12,274 Relmada Therapeutics shares in Q4 2024, an estimated $39.8K.
  • Mariner first reported a position in Relmada Therapeutics in Q4 2022 and held it in 8 quarters.
  • Mariner's Relmada Therapeutics position peaked at $143K in Q4 2022.
  • 48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Mariner's 13F filing for Q4 2024, filed 13 Feb 2025.